Abiopharma

🔍 Browers Blaine (Executive)

Company: Cadre Holdings, Inc. (CDRE)

Report Date: 2026-03-30

Detailed Transactions and Holdings:

• Acquired 15,333 shares of Restricted Stock Units (Derivative)
  Date: 2026-03-30 | Code: A | equity_swap_involved: 0 | shares_owned_after: 15,333.00 | transaction_form_type: 4 | Footnotes: F1, F1, F1
• Acquired 49,664 shares of Stock Option (right to purchase) at $29.39 per share (Derivative)
  Date: 2026-03-30 | Code: A | Expires: 2036-03-30 | equity_swap_involved: 0 | shares_owned_after: 49,664.00 | transaction_form_type: 4 | Footnotes: F2

Footnotes:

• F1: Comprised of a restricted stock units award granted under Cadre Holdings, Inc.'s (the "Issuer") 2021 Stock Incentive Plan (the "Plan"), consisting of 15,333 restricted shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock"). Of those shares, 5,111 shares will vest and become non-forfeitable on each of March 30, 2027, March 30, 2028, and March 30, 2029, respectively.
• F2: The option to purchase shares of the Issuer's Common Stock was granted under the Plan. Options to purchase 16,556 shares of the Issuer's Common Stock will vest and become exercisable on March 30, 2027, and options to purchase 16,554 shares of the Issuer's Common Stock will vest and become exercisable on each of March 30, 2028, and March 30, 2029, respectively.